Galvis Virgilio, Tello Alejandro, Ortiz Alvaro I, Escaf Luis C
Centro Oftalmológico Virgilio Galvis, Floridablanca.
Department of Ophthalmology, Faculty of Health Sciences, Universidad Autónoma de Bucaramanga, Bucaramanga.
Clin Ophthalmol. 2017 Apr 7;11:657-668. doi: 10.2147/OPTH.S101386. eCollection 2017.
Corneal cross-linking (CXL) is an option that in the last decade has demonstrated its efficacy and safety in halting the progression of keratoconus (KCN) and other corneal ectasias. Its indication has been extended beyond the classic definition that required evidence of KCN progression, especially in the presence of some risk factors for a possible progression (particularly the younger age). However, the results can be still somewhat variable today. There are several protocols, each with its own advantages and disadvantages. Some predictors of CXL outcome have been identified. We will review the current knowledge on patient selection for CXL, its indications, and options in special cases (such as thin corneas).
角膜交联术（CXL）是一种在过去十年中已证明其在阻止圆锥角膜（KCN）和其他角膜扩张进展方面的有效性和安全性的方法。其适应症已超出了需要KCN进展证据的经典定义，特别是在存在一些可能进展的危险因素（尤其是较年轻的年龄）的情况下。然而，如今结果仍可能存在一定差异。有几种方案，每种都有其自身的优缺点。已经确定了一些角膜交联术结果的预测因素。我们将回顾目前关于角膜交联术患者选择、其适应症以及特殊情况（如薄角膜）下的选择的知识。
